BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the fourth quarter and full year ended December 31, 2014.
The Research Division of BioTelemetry
Welcome to BioTelemetry Research, formerly Cardiocore. Our acquisition by BioTelemetry, Inc. (NASDAQ: BEAT) in 2012 enabled us to grow beyond our core roots, both in size and service offerings. Today as BioTelemetry Research, we are a member of the world’s largest cardiac data network — processing over 2 billion heartbeats a day, while supporting more than 20,000 sites and 30,000 devices monthly, as well as monitoring over 500,000 patients a year. In addition to industry-leading global cardiovascular monitoring, we have now expanded our clinical trial services in two important areas: advanced imaging services and respiratory testing. Every day, our global services teams meet the demands of Phase I-IV trials for the world’s largest pharmaceutical organizations, specialty pharmaceutical firms, emerging biotechnology companies, and medical device manufacturers.
Blood Pressure Evaluation During Early Phase Trials
More attention is being paid to blood pressure (BP) effects in new chemical entities under development for non-hypertension indications, especially when these are not anticipated and not thoroughly defined during drug development.
Join in this free webinar with industry experts Sandra Chica, MD and Polina Voloshko, MD as they aim to describe novel medical imaging approaches and methodologies to help sponsors maximize clinical trial efficiency along the development pathway. Register today to save your seat!